Share Name Share Symbol Market Type Share ISIN Share Description
GlaxoSmithKline LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +4.80p +0.35% 1,358.00p 1,356.60p 1,357.20p 1,363.40p 1,351.40p 1,351.40p 8,353,763 16:35:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,889.0 1,939.0 18.8 72.2 67,328.27

GlaxoSmithKline Share Discussion Threads

Showing 16351 to 16373 of 16375 messages
Chat Pages: 655  654  653  652  651  650  649  648  647  646  645  644  Older
DateSubjectAuthorDiscuss
19/1/2018
09:14
Yes, 22 Feb for 23p per GSK share ..... ;0)
tradermichael
19/1/2018
08:46
Div forecast for the finals in February is 23p for this quarter.
montyhedge
19/1/2018
08:44
At least your getting paid every 13 weeks while we wait for 1575p again.
montyhedge
19/1/2018
08:38
I bought in GSK today believe it will be a very good investment in medium/ long term. Wait and see?
kcsham
19/1/2018
07:07
The company directors are the only ones that have ever made any serious cash out of the company in my opinion!
gbh2
18/1/2018
21:49
OXB doing well based on CAR-T potential
bountyhunter
18/1/2018
20:58
GlaxoSmithKline and NeuroMetrix to develop wearable pain relief products HTTPS://www.zenopa.com/news/801843908/glaxosmithkline-and-neurometrix-to-develop-wearable-pain-relief-products
philanderer
18/1/2018
20:48
The pe on Shire is certainly not high, look again...
romeike
18/1/2018
18:33
Getting worse hTTps://www.semissourian.com/story/2477350.html
buywell3
18/1/2018
17:55
Re Voltaren - generic gels out already in CH - small fraction of the price. Quick! Generic manufacturers are getting quicker and quicker.
alphorn
18/1/2018
17:38
did either of you also check AZN? yield not as good as GSK but other fundamentals not bad
bountyhunter
18/1/2018
14:29
Rom Looked at Shire very expensive, my view, high p.e, yield 0.71%. GSK potential forecast p.e 12 Yield 6.10% I will stick with GSK.
montyhedge
18/1/2018
14:23
A good price trader for a long term hold. Shire worth a look also at its current price. Not often a FTSE100 stock offers the opportunity of a potential 50% increase.
romeike
18/1/2018
13:04
GlaxoSmithKline supplies an estimated seven per cent of the world's pharmaceutical market and has six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions. Plenty of room for expansion and growth here ...... ;0)
tradermichael
18/1/2018
10:27
That will do.
montyhedge
18/1/2018
09:52
18th jan Liberum buy tp 1630p down from 1760p
philanderer
18/1/2018
09:14
Trip tops, why are you posting on this thread? If, as you say, these things are already known, why are they still doing, and planning yet to do, these studies?
jadeticl3
18/1/2018
09:05
Looking good for IMM's Lupuzor to take all GSK's Benlysta sales, and is already known to be safer and more efficaceous: 18 JANUARY 2018 ImmuPharma PLC Completion of Lupuzor(TM) Pivotal Phase III Study and Initiation of Follow Up Study ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor(TM), its lead programme for the potential breakthrough compound for Lupus, is now complete, following the last patient having attended their final assessment. Final patient data from the trial are being collated and entered into the database, checked and analysed. This process is ongoing and top line results remain on track to be reported by the end of Q1 2018. At completion, we continue to observe a robust safety profile over the 12 month period of patients' participation in the trial. Separately, following requests from both Investigators and patients involved in the Phase III study, ImmuPharma is initiating a "follow-up" study permitting eligible patients from the completed Phase III study, to receive Lupuzor(TM) (plus "Standard of Care") for a further six months in an open-label scheme. The results will be gathered as an "extension" open label study, independent of the pivotal Phase III trial which is now completed. Commenting on the trial update, Robert Zimmer (MD, PhD), President & CSO said: "We are delighted to announce this major milestone for ImmuPharma in having completed on track this pivotal Phase III trial for Lupuzor(TM). "I would like to take this opportunity of thanking all of our Clinical Investigators; Simbec-Orion, our clinical research organisation and the ImmuPharma France team led by Dr Fanny Valleix, Head of Clinical Research. All were paramount in the execution and completion of this trial. "With the continued robust safety achieved over this trial, we look forward with continued confidence to reporting top line results of the study this Q1 2018."
top tips
18/1/2018
00:32
Pharma giant GlaxoSmithKline gave up early gains to finish just 4.2p higher at £13.59 after it unveiled its plan to pull back its operations in Africa as part of chief executive Emma Walmsley’s shake-up. http://www.telegraph.co.uk/business/2018/01/17/market-report-imperial-dips-deal-talk-stubbed/
philanderer
17/1/2018
22:29
Polaris: ' I took the pay cut and moved back to the UK, after 13 years away. I'm still comfortable - overseas pay can be crazily good - but i have my life back under control, reduced stress and a job that challenges me in different ways every day. ' -- I totally get this :) Been away on and off for 25 years, this last long stint at 9.5 years, with Singapore [3rd time lol] and then 2 more *x-postings afterwards. Just been back to London for 3 days, got home this pm - good grief how it's changed - my old local ['boozer' back in the 90s] is now a '''champagne and oyster bar''' FFS. Moving back permanently in July > bring it on, a predictable 'base and routine' will be great! To an earlier quality poster/point re: targets and volumes. Today the volume was 11.05/8.16M [daily/30-day average], ie 135% with +42p/+0.31% on the share price Nice to see well over average vol backing rises like that.
jrphoenixw2
17/1/2018
18:41
Re #284. Another clever approach with Voltaren is to take the off-patent active and come up with the new presentations at premium prices. Smart moves which could be followed for other off-patent actives.
alphorn
17/1/2018
14:50
Barclays saying HIV and Shingles Vac to drive growth. These look good value, chaps.
montyhedge
17/1/2018
13:29
17th jan TraderMichael buy tp 1950p unchanged
tradermichael
Chat Pages: 655  654  653  652  651  650  649  648  647  646  645  644  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180119 17:37:59